Lurasidone (Latuda®) is a new atypical antipsychotic indicated for the treatment of schizophrenia in adults. The once daily tablet should be taken with meals to ensure optimal absorption.

Lurasidone is less likely to cause metabolic side effects than other antipsychotics. This offers another treatment option for patients who have experienced significant weight gain with other treatments. Common side effects include drowsiness, akathisia, nausea, and parkinsonism.

Lurasidone is mainly metabolised via the cytochrome-P450 pathway, CYP3A4 in particular. Medicines that inhibit this pathway will increase patient exposure, whilst inducers will reduce exposure to lurasidone. For this reason, co-administration is contraindicated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir, and voriconazole) and strong CYP3A4 inducers (e.g. rifampicin, St John’s wort, phenytoin, and carbamazapine).

The Pharmaceutical Benefits Advisory Committee recommended streamlined authority listing and determined 80mg lurasidone to be equi-effective with 114.15mg of ziprasidone.

References:

  1. Latuda® (lurasidone) Australian approved product information. Melbourne: Commercial Eyes Pty Limited. Approved 16 April 2014.
  2. O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013; 5: 459–470.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates